The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances in the context of a so-called open house procedure:

icatibant (B06AC02)

Prucalopride (A06AX05)

Under standard contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest contract start date is 01.01.2022. On this basis, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest contract start date is 01.01.2022. On this basis, the contract period is a maximum of 24 months.